Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Getting to 90-90-90 in paediatric HIV: What is needed?

Davies MA, Pinto J, Bras M.

J Int AIDS Soc. 2015 Dec 2;18(7Suppl 6):20770. doi: 10.7448/IAS.18.7.20770. eCollection 2015. No abstract available.

2.

Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV-Infected Subjects With Aging Biomarkers.

Dumond JB, Chen J, Cottrell M, Trezza CR, Prince H, Sykes C, Torrice C, White N, Malone S, Wang R, Patterson KB, Sharpless NE, Forrest A.

CPT Pharmacometrics Syst Pharmacol. 2017 Feb;6(2):128-135. doi: 10.1002/psp4.12151. Epub 2016 Dec 29.

3.

Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation.

Curley P, Rajoli RK, Moss DM, Liptrott NJ, Letendre S, Owen A, Siccardi M.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01841-16. doi: 10.1128/AAC.01841-16. Print 2017 Jan.

PMID:
27799216
4.

Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.

Robarge JD, Metzger IF, Lu J, Thong N, Skaar TC, Desta Z, Bies RR.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01813-16. doi: 10.1128/AAC.01813-16. Print 2017 Jan.

PMID:
27799204
5.

Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV.

Hui KH, Lee SS, Lam TN.

CPT Pharmacometrics Syst Pharmacol. 2016 Apr;5(4):182-91. doi: 10.1002/psp4.12067. Epub 2016 Apr 6.

6.

Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis.

Nightingale S, Chau TT, Fisher M, Nelson M, Winston A, Else L, Carr DF, Taylor S, Ustianowski A, Back D, Pirmohamed M, Solomon T, Farrar J, Törok ME, Khoo S.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4511-8. doi: 10.1128/AAC.00280-16. Print 2016 Aug.

7.

Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.

Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Gibb DM, Burger D, Walker AS, McIlleron H.

J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):161-8. doi: 10.1097/QAI.0000000000001032.

8.

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.

Bienczak A, Cook A, Wiesner L, Olagunju A, Mulenga V, Kityo C, Kekitiinwa A, Owen A, Walker AS, Gibb DM, McIlleron H, Burger D, Denti P.

Br J Clin Pharmacol. 2016 Jul;82(1):185-98. doi: 10.1111/bcp.12934. Epub 2016 Apr 25.

9.

Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.

Dickinson L, Amin J, Else L, Boffito M, Egan D, Owen A, Khoo S, Back D, Orrell C, Clarke A, Losso M, Phanuphak P, Carey D, Cooper DA, Emery S, Puls R.

Clin Pharmacokinet. 2016 Jul;55(7):861-73. doi: 10.1007/s40262-015-0360-5.

10.

CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women.

Röhrich CR, Drögemöller BI, Ikediobi O, van der Merwe L, Grobbelaar N, Wright GE, McGregor N, Warnich L.

AIDS Res Hum Retroviruses. 2016 Jun;32(6):529-38. doi: 10.1089/AID.2015.0048. Epub 2016 Jan 29.

PMID:
26655325
11.

The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected children.

Vreeman RC, Scanlon ML, McHenry MS, Nyandiko WM.

J Int AIDS Soc. 2015 Dec 2;18(Suppl 6):20258. doi: 10.7448/IAS.18.7.20258. eCollection 2015.

12.

A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study.

Damronglerd P, Sukasem C, Thipmontree W, Puangpetch A, Kiertiburanakul S.

Pharmgenomics Pers Med. 2015 Oct 3;8:155-62. doi: 10.2147/PGPM.S86446. eCollection 2015.

13.

Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.

Cummins NW, Neuhaus J, Chu H, Neaton J, Wyen C, Rockstroh JK, Skiest DJ, Boyd MA, Khoo S, Rotger M, Telenti A, Weinshilboum R, Badley AD; INSIGHT Study Group..

EBioMedicine. 2015 May 12;2(7):706-12. doi: 10.1016/j.ebiom.2015.05.012. eCollection 2015 Jul.

14.

Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.

Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, Supparatpinyo K, Mohapi L, Gupta A, Benson CA, Kim P, Fletcher CV; AIDS Clinical Trials Group A5279 Study Team..

Clin Infect Dis. 2015 Oct 15;61(8):1322-7. doi: 10.1093/cid/civ464. Epub 2015 Jun 16.

15.

CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.

Dhoro M, Zvada S, Ngara B, Nhachi C, Kadzirange G, Chonzi P, Masimirembwa C.

BMC Pharmacol Toxicol. 2015 Mar 27;16:4. doi: 10.1186/s40360-015-0004-2.

16.

Measuring adherence to antiretroviral therapy in children and adolescents in western Kenya.

Vreeman RC, Nyandiko WM, Liu H, Tu W, Scanlon ML, Slaven JE, Ayaya SO, Inui TS.

J Int AIDS Soc. 2014 Nov 25;17:19227. doi: 10.7448/IAS.17.1.19227. eCollection 2014.

17.

Albumin nanoparticles coated with polysorbate 80 as a novel drug carrier for the delivery of antiretroviral drug-Efavirenz.

Jenita JL, Chocalingam V, Wilson B.

Int J Pharm Investig. 2014 Jul;4(3):142-8. doi: 10.4103/2230-973X.138348.

18.

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.

Mukonzo JK, Owen JS, Ogwal-Okeng J, Kuteesa RB, Nanzigu S, Sewankambo N, Thabane L, Gustafsson LL, Ross C, Aklillu E.

PLoS One. 2014 Jan 31;9(1):e86919. doi: 10.1371/journal.pone.0086919. eCollection 2014.

19.

Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.

Salem AH, Fletcher CV, Brundage RC.

Antimicrob Agents Chemother. 2014;58(1):136-43. doi: 10.1128/AAC.01738-13. Epub 2013 Oct 21.

20.

Population pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.

Abdelhady AM, Desta Z, Jiang F, Yeo CW, Shin JG, Overholser BR.

J Clin Pharmacol. 2014 Jan;54(1):87-96. doi: 10.1002/jcph.208. Epub 2013 Nov 19.

Supplemental Content

Support Center